Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
Checked against the public recordLast updated Nov 21, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Sophia Genetics SAS
- Interventions being studied
- Other: Predictive models (data collection)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adult ≥18 years old * Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV) * Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK) * Cohort A: Received first line treatment with pembrolizumab monotherapy * Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy * Cohort C: Received first line treatment with chemotherapy doublet Exclusion Criteria: * Prior anti-cancer therapy for actual stage IV NSCLC * Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging) * Patients participating in other clinical trials that modify the standard of care
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Holden Comprehensive Cancer Center at University of Iowa Health CareIowa City, Iowa
- UMASS Memorial HealthWorcester, Massachusetts
- Mayo ClinicRochester, Minnesota
- Roswell Park Comprehensive Cancer CenterBuffalo, New York
- Huntsman Cancer InstituteSalt Lake City, Utah
- Carbone Comprehensive Cancer Center at University of WisconsinMadison, Wisconsin
- DASA - Hospital BrasiliaBrasília
- DASA - Hospital de NiteroiNiterói
- DASA - Hospital São LucasRio de Janeiro
- DASA - Hospital Nove De JulhoSão Paulo
- AC CamargoSão Paulo
- Sunnybrook Health Sciences Centre TorontoToronto
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 21, 2024. Always confirm current availability with the study team.